OncoMatch/Clinical Trials/NCT06758713
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Is NCT06758713 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAR-T for multiple myeloma.
Treatment: CAR-T — This is a single center, open-label, dose-escalation/expansion clinical study to evaluate the safety and effectiveness of Fourth-Generation CAR-T, and determine the recommended dose of the CAR T-cells for patients with Multiple Myeloma，B-cell lymphoma and other hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Required: CD7 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: targeting the same molecule
Having received CAR-T therapy targeting the same molecule
Cannot have received: immunotargeted therapy
Exception: targeting the same molecules
Having received other immunotargeted therapy targeting the same molecules
Cannot have received: allogeneic hematopoietic stem cell transplantation
Having received allogeneic hematopoietic stem cell transplantation
Cannot have received: gene therapy product
prior treatment with any gene therapy product in the past three months
Lab requirements
Blood counts
White blood cell count ≥ 3.0 × 10e9/L; Absolute neutrophil ≥ 1.0 × 10e9/L; Lymphocyte count ≥ 0.5 × 10e9/L; Platelet count ≥ 50 × 10e9/L (not required for leukemia, multiple myeloma, and lymphoma)
Kidney function
Serum creatinine ≤ 2.5 mg/dl
Liver function
Serum total bilirubin (TBIL) ≤ 2.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN, or 5 ULN if liver dysfunction is primarily due to tumor invasion
Cardiac function
Good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 55%
The clinical trial values during the screening period meet the following criteria: 1. White blood cell count ≥ 3.0 × 10e9/L; Absolute neutrophil ≥ 1.0 × 10e9/L; Lymphocyte count ≥ 0.5 × 10e9/L. (The growth factor support is allowed, but growth factor must not have been received within 7 days prior to laboratory testing); 2. Platelet count ≥ 50 × 10e9/L (No blood transfusion support within 7 days prior to laboratory tests.); Note: Patients with leukemia, multiple myeloma, and lymphoma are not subject to the above blood picture requirements; 3. Biochemical indicators Serum total bilirubin (TBIL) ≤ 2.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN, or 5 ULN if liver dysfunction is primarily due to tumor invasion); 6. Cardiac function: Subjects must have good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 55%;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06758713 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, immunotargeted therapy, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Does this trial require CD7?
Yes, CD7 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages